OncoMatch/Clinical Trials/NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Is NCT06899126 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Trastuzumab Deruxtecan and pembrolizumab for non-small cell lung cancer.
Treatment: Trastuzumab Deruxtecan · pembrolizumab · Pemetrexed · Platinum Chemotherapy — This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) expression (testing required; no eligibility threshold specified)
Required: HER2 (ERBB2) overexpression
Required: HER2 (ERBB2) wild-type
Disease stage
Required: Stage IIIB, IIIC, IV
Prior therapy
Cannot have received: systemic anticancer therapy for advanced or metastatic non-squamous nsclc
Exception: adjuvant or neoadjuvant therapy allowed if last dose ≥6 months before first trial dose and disease progressed ≥6 months after last dose
Cannot have received: topoisomerase i-targeting chemotherapeutic agent (including adc)
Cannot have received: her2-targeted antibody-based anticancer therapy
Lab requirements
Cardiac function
no medical history of mi within 6 months before randomization/enrollment or symptomatic chf (nyha class ii to class iv). qtc prolongation to >480 ms based on the average of the screening triplicate 12-lead ecg.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Oncology & Hematology, LLC · Anchorage, Alaska
- Orange Coast Memorial Medical Center Fountain Valley · Fountain Valley, California
- California Research Institute · Los Angeles, California
- Los Angeles Cancer Network (LACN) · Los Angeles, California
- Providence Medical Foundation · Santa Rosa, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06899126 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy for advanced or metastatic non-squamous nsclc, topoisomerase i-targeting chemotherapeutic agent (including adc), her2-targeted antibody-based anticancer therapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 expression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify